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The length, the composition, the quality and the characteristics of value chains essentially determine 
the corporate as well as the macroeconomic performance of the economic sectors and industries. 
Hungary has a strong tradition in the pharmaceutical industry but its dynamising impact seems 
to be limited on the economy. The aim of this paper is to detect and reveal the specialties of the 
Hungarian pharmaceutical industry both in space and time by a value chain analysis. Our method 
is partly quantitative, we use an input-output analysis; and partly qualitative, relying on interviews 
with the representatives of pharmaceutical companies. We found that the Hungarian pharma value 
chain is really special, having relatively short backward and forward linkages with mainly indirect 
value-added contribution as well as high import content of exports. However, our company inter-
views revealed the fundamental differences between original and generic value chains – i.e. again 
a pharma industry-specifi c distinction. Having relatively little original and more substantial generic 
production in Hungary explains much of the value chain specialties, which leaves its mark on the 
limited impact of the industry on the national economy. 
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INTRODUCTION
The macroeconomic structure of a country and its strategic management are fac-
ing several challenges. The new technological era is changing the value-added 
capabilities, the efficiency and the relative importance of industries, since to a 
different extent it influences the research and development (R&D) content of the 
industries, the level how each production process can be automatized or how the 
sales structure shrinks. At the same time, besides the speeding up of reproduction 
processes, the interfering crises enhance instability and, as a consequence, the 
capability to monitor the spillover effects. Hence, even if the pure structure of 
the economic sectors does not change, their value creating power, its shift among 
the production phases as well as the performance of the industries in time do 
change. The efficiency of the economic policy and strategy will crash on a stand-
ard structural evaluation basis unless it understands the nature of value chains and 
their specialities by industries.
The length, the composition, the quality and the characteristics of value chains 
fundamentally determine the corporate as well as the macroeconomic perform-
ance of the economic sectors and industries. Moreover, the direct and indirect 
economic-dynamising impacts of the industries also highly depend on these 
links. Overall, the specialisation in certain branches demand a deeper than ever 
research on the value chain features, owing to the peculiar forward and backward 
linkages.
The value chain approach is based on the process view of production, where 
the various subsystems are all connected to each other presenting transformation 
processes and output. The efficiency of value chain activities determines the costs 
and profits of the firm (Porter 1985). Many value chains do not confine them-
selves to a country, which gave rise to the emergence of international or global 
value chains (GVCs). GVCs have proliferated in the global economy in the last 
decades. According to De Backer – Mirodout (2013: 8) “A global value chain in-
volves all the activities that firms engage in, at home or abroad, to bring a product 
to the market, from conception to final use”. The production of more and more in-
dustries is carried out in GVCs, where an increasing number of countries and loca-
tions are involved in the production of a good or service, depending on the techni-
cal fragmentation of production, the tradability of intermediary goods and related 
services, and the level of trade liberalisation of industries at various (regional and 
global) levels. Owing to these factors, the level of geographic dispersion of the 
activities of individual industries is different, though changing over time.  
The pharmaceutical industry played a special role in the Hungarian economy 
and economic history throughout the 20th century. At the same time, it is an intel-
ligent industry performing relatively high value added with a constant demand 
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for high level human resources and technological infrastructure. Moreover, the 
pharmaceutical industry used to be and it is a successful, high brand sector both 
domestically and in the international markets.  
The aim of this paper is to detect and reveal the specialities of the Hungarian 
pharmaceutical industry both in space and time by a value chain analysis. In order 
to do so we have identified the following research questions:
– What is the position of the pharmaceutical industry in the Hungarian econo-
my in terms of output, value added and expenditure?
– What characterises the pharma industry in terms of its domestic backward 
and forward linkages?
– What is the international trade performance of the industry?
– What features can be detected regarding the international backward and for-
ward linkages via trade, with special attention to the value added and import 
content of export as well as the country-industry structures of the upward and 
downward chains?
– What historic and technological reasons can explain the revealed structure of 
the Hungarian pharmaceutical industry?
The research is partly quantitative; it monitors the local as well as the interna-
tional linkages by an input-output analysis. Interviews with the pharmaceutical 
company representatives enrich the data and the calculations through a better 
understanding of the figures and the individual company features. Moreover, the 
Hungarian results are embedded in a general industry overview as well as they 
receive a historic perspective so that the dynamic approach could support a de-
tailed, nonetheless, comprehensive pharma value chain research.
The paper is structured as follows. We show the industry environment and 
background: the most important characteristics of the pharma industry in general 
and the Hungarian pharma industry in particular in Section 1. Section 2 summa-
rises the results of the literature concerning the analysis of the value chains at the 
industry level and in the pharma industry. Following the applied methodology, 
Section 3 of the paper presents the quantitative and qualitative analysis (company 
interviews) and Sections 4 and 5 show their results. The conclusions contain the 
most important findings in Section 6. 
1. OVERVIEW OF THE PHARMA INDUSTRY
The pharma industry is specialised in highly technology intensive activities, with 
the highest R&D per output indicator among manufacturing industries. Nowadays, 
the pharma industry is highly globalised and the value chains are reorganised at 
the international level (Haakonsoon 2009). The industry is moving towards a new 
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model, where first, profits are significantly lower than in the previous era, sec-
ond, connected to that, there is an ongoing consolidation, mainly through merg-
ers and acquisitions. Thus, the main global players are those large pharma firms 
which have been created in a process of mega mergers and acquisitions, includ-
ing cross-border ones. The link between these two phenomena, i.e. lower profits 
and mega mergers and acquisitions, can be traced in the previously high product 
prices based on the exceedingly high costs of product (molecule) development. 
With the expiry of previous patents (and the appearance of new competitors with 
generic products), companies strive to find new molecules, a process which is in-
creasingly costly. Thus, a firm either outsources basic R&D or tries to find small 
firms with potentially successful molecules. In these new circumstances, pharma 
companies from the “mid-developed” countries, such as Hungary cannot really 
compete with the Big Pharma (leading pharma companies of the developed coun-
tries) because of their limited resources (Antalóczy – Sass 2018).
The product of the industry, medicines, is a special good. One of their most 
important characteristics is that they should be safe and effective. That is why the 
industry is highly regulated and firms must fulfil a series of requirements, both 
concerning the production processes and the introduction of a good on the mar-
ket. These regulations are still mainly at the national level, resulting in a highly 
fragmented global market (Haakonsoon 2009). Another important feature of the 
industry is that the production of an active agent or substance consists of thou-
sands of processes, resulting in a long value chain. At each step the company, in 
principle, may decide about keeping it within the company or outsourcing it to 
an independent firm. However, because of the highly innovative nature of the 
industry and because of producing a product for which quality and health secu-
rity issues as well as the regulatory requirements are of paramount importance, 
a large part of the value chain is “kept” within the companies. (The regulatory re-
quirements make the process of involving “outside” firms more burdensome than 
in other industries.) As a result, the pharma value chain is highly standardised 
and vertically integrated. Thus, the backward and forward linkages of the pharma 
industry are negligible compared to other industries, especially in production. 
One must mention one more specialty of the pharma industry: the distinction 
between original and generic pharma producers, which differ from each other in 
many respects (Frew et al. 2015). Original pharma producers invent, develop, 
patent and produce their own “original” molecules. Generic pharma producers 
are allowed to produce and sell the same chemical substance after the expiry of 
the patent of the original drug. After the expiry of the patent, when generic drugs 
enter the market, prices usually fall for both the original product and its generic 
equivalents. Obviously, the two types of pharma firms differ from each other 
in many characteristics. Original pharma producers spend considerably more on 
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R&D, their value chain is much longer (involves more steps, due to the higher 
complexity of their activities, a higher number of various regulations to be met 
and so on) (See Annex). Thus, in principle, the issue of outsourcing and coop-
eration with economic and non-economic actors may come up more frequently, 
compared to the generic producers, and could result in a more intense contact, 
and, thus, effect with and on the economy.
This short introduction to the pharma industry serves to underline the fact that 
compared to other industries, pharmaceuticals have a large number of special 
features.  
1.1. The Hungarian pharma industry
Hungary has a long tradition in pharmaceuticals which dates back to the begin-
ning of the 20th  century. Three of the four leading pharma companies (Richter 
Gedeon, Chinoin and Egis) were established between 1901 and 1913, while one 
of the predecessors of the fourth (Biogal) in 1950. They are specialised in different 
areas: Richter Gedeon in pharma production based on natural materials, Chinoin 
in synthetic pharma production and Egis in nutrition products. After World War 
II, the pharmaceutical tradition was further reinforced during the CMEA1 area, 
Hungary being specialized in the socialist division of labour in the production of 
drugs and being responsible for supplying drugs to other CMEA countries (An-
talóczy 1999). Thus, the industry was highly export-oriented, mainly towards the 
CMEA markets, but could sell some of its products in other countries as well. In 
the pre-1989 period, basic research was carried out by academic institutions and 
applied R&D was assigned to industrial branch research institutes (Felker et al. 
1997). There were six major companies operating in the industry (the above men-
tioned four plus Humán and Alkaloida, smaller-sized and highly specialised), due 
to the nationalisation and merger of smaller companies into larger ones at the end 
of the 40s, specialising again in various areas, partly now related to the CMEA 
needs. Furthermore, in the planned economy period, these firms were all char-
acterised by a very strong level of vertical integration, and even other activities 
formed part of the company structure, which in market economies are generally 
outsourced to independent companies (for example, catering, maintenance serv-
ices, horticultural services, kindergarten and crèche services for the children of 
the employees). Furthermore, this feature was reinforced by the autarchic nature 
1  The Council for Mutual Economic Assistance (CMEA, but colloquially called also as 
COMECON) was the economic organisation of socialist countries between 1949 and 1991, 
organising and regulating trade among the participating countries at the state level. 
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of the planned economy, whereby what could be produced locally, was produced 
there, regardless of the costs. The protection of patent rights evolved in Hungary 
towards the generic structure, thus the processes of producing a molecule, and 
not the molecule itself was protected and patented. This type of research speciali-
sation and special knowledge characterised the Hungarian pharma R&D at that 
time. When they started to export to outside the CMEA, starting from the 70s, the 
companies had to fulfil international safety regulations, which again reinforced 
the trend of keeping the overwhelming majority of production and production-
related activities within the firm in order to be able to control them.
At the beginning of the transition period, liberalisation of foreign trade, and 
thus, market access provided to the competitive Western firms significantly re-
duced the domestic market shares of these companies. Furthermore, as being 
among the most attractive firms, the government decided to privatise the leading 
firms to foreign investors, resulting in a strong foreign presence in the industry. 
Among the six firms, only Richter Gedeon was kept under domestic control 
(but in dispersed foreign majority ownership) as its shares were introduced on 
the Budapest stock exchange. The other five companies were sold to foreign 
pharma firms.
Besides the long tradition, the contribution of the pharmaceutical industry to 
the Hungarian economy is well above the regional average (Table 1). The indus-
try in Hungary is among the top employers and investors. The ratio of its share 
in manufacturing production and value added shows that the activities can be 
characterised as highly complex. Its productivity indicators are also leading in 
the region.
Nowadays, the characteristics and value chains of the Hungarian pharma com-
panies are, thus, determined on the one hand by their heritage from the planned 
economy period (path dependency), and on the other hand by the different ways 
they were privatised.  Their privatisation was different from that of other firms, 
as the pharma firms could maintain their integrity (only those activities were 
separated which did not have a close connection with pharma production, such 
as production of cosmetics or pesticides, and in certain cases “auxiliary services” 
to the employees, such as the kindergarten). Thus, the whole vertical integration 
of pharma production was privatised, and their future was determined by the new 
owner.
In the case of Chinoin, the French Sanofi, one of the largest pharma firms in 
the world first acquired a minority, then a majority, and later full ownership of 
the Hungarian firm. Sanofi is one of the leading original producers, but it has a 
generic arm, too. The new owner has gradually changed the vertically integrated 
value chain of Chinoin. Their R&D activities were transferred to other (foreign) 
affiliates; the Hungarian affiliate received the process development of chemical 
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production only – resulting in an almost complete loss of its R&D activities. 
Another such area was marketing. What remained at the Hungarian affiliate was 
generic production (substances, tablets, effervescent tablets, ampules, injections) 
and the logistics centre. Thus, the value chain has been narrowed down signifi-
cantly: low value-added activities remained in Hungary, and there were no high 
value-added ones (re)located here. The value chain has minor links with other 
industries. Thus, the case of Chinoin can be characterised as a generic value chain 
with a focus on production. 
Biogal was acquired by another leading pharma firm, the top generic producer 
in the world, the Israeli Teva. Similarly to Chinoin, the value chain was shortened 
here as well, with production and related development remaining in Hungary. 
However, the Hungarian company, located in Debrecen is the second largest pro-
duction site of Teva. Here again, we can speak about a generic value chain with 
a focus on production.
Richter Gedeon had a different way of privatisation: its shares were introduced 
on the Budapest stock exchange in three tranches. The main owners are (foreign) 
portfolio investors, the ownership structure is dispersed, and decisions of strate-
gic importance are made in Hungary by the Hungarian management. The value 
chain is basically intact from R&D through production till sales. The manage-
ment of Richter Gedeon organises and outsources-offshores various functions. 
Table 1. Selected characteristics of the Hungarian pharmaceutical industry in international 
comparison (2017)
Austria Czechia Hungary Poland Slovakia
Number of enterprises 89 86 92 350 34
Production value (million EUR) 4130.3 1380.2 3237.5 3754.6 185.1
Wages and salaries (million 
EUR)
767.3 153.2 440.2 392.6 33.1
Gross investment in tangible 
goods (million EUR)
269.9 76.3 264.8 164.2 15.1
Persons employed 14860 10083 18928 22634 2287
Share of production value in 
manufacturing total (%) (2016)
2.3 0.8 3.2 1.3 0.3
Share of VA in manufacturing 
total (%)
3.4 1.2 5.7 1.7 0.5
Wage adjusted labour 
productivity (apparent labour 
productivity by average 
personnel costs) (%) (2016)
170.6 224.2 246.1 228.1 146.8
Source: Eurostat Annual detailed enterprise statistics for industry (NACE Rev.2).
Note: Manufacture of basic pharmaceutical products and pharmaceutical preparations (C21).
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The company is mainly a generic producer, but there is an original “arm” as well, 
resulting in own drugs. Thus, its value chain is more complex, than in the cases 
of the previous two companies.
The fourth company, Egis, was privatised to the French Servier. Servier is 
among the smaller pharma players and is an original company. It has not inte-
grated Egis into its own value chain, as in the cases of the first two companies. It 
has two separate value chains: generic and original. The generic is organised fully 
by Egis from development to marketing. In the original, it is rather involved in 
various activities in the value chain of Servier.
Thus, due to their heritage and privatisation, the four leading pharma compa-
nies in Hungary have now different value chain combinations.
2. LITERATURE OVERVIEW
The specialties of the pharma value chain are not often analysed in the literature. 
Related to our article, the analysis of Medina et al. (2017) examines among oth-
ers the differences of value chains in countries and industries based on industry 
level data and input-output tables in the European Union (EU) between 2005 and 
2014. Industrial value chains are perceived as which contain all value-added in 
the interlinked industries and countries, through which the ready-made product 
is delivered to the final users. According to their results, in the EU, individual 
industries differ from each other in terms of their forward and backward link-
ages. “Key industries” are those which have strong forward and backward link-
ages. They found nine such industries, such as e.g. metallurgy, timber, rubber and 
chemical industry. Those industries belong to the second category which have 
strong backward linkages and they sell readymade products to households, the 
government or for investment purposes. There are eight such industries, such as 
e.g. the automotive, food, machinery, electronics and textile industries. There is 
one industry with strong forward linkages: the coal industry. From the point of 
view of our topic, the most important result is that the authors have found one “in-
dependent” industry, which has both weak backward and forward linkages – that 
is the pharma industry. Between 2005 and 2014, there was just a slight increase 
in the backward linkage index of this industry, and its forward linkage index has 
not changed at all. The authors have calculated the value-added multiplier of 
the individual industries, which, in the case of the pharma industry, in spite of 
the minimal backward and forward linkages, does not deviate significantly from 
those of the other industries. (It is significantly lower only in the cases of the 
coal industry and metallurgy.) According to the results of further investigations, 
at the EU-level, the pharma industry is the third least integrated industry, which 
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is obviously in connection with the above described “independent” nature of this 
industry. At the same time, the indicator of domestic value-added is among the 
highest for the pharma industry. 
Other publications also underline the specialties of the pharma industry, es-
pecially its “independent” nature. Sturgeon – Kawakami (2010) concentrated on 
the electronics industry, but according to the information provided, we can get 
some hints about the pharma industry compared to electronics. The authors ana-
lysed trade in intermediates in eleven manufacturing industries. The share of the 
pharma industry in the total intermediates’ trade of these eleven manufacturing 
industries was 0% in 1998, with a value of 0 million USD (thus there was basi-
cally no trade in intermediates in our analysed industry), and by 2006 this share 
grew to 1.7 % only with a value of 66.503 million USD. It is interesting to com-
pare these data with those of the electronics and automotive industries: in 2006 
these were 43.3% and 1,670,940 million USD; and 21.4% and 824,392 million 
USD, respectively.
There are a few country-level analyses about the characteristics of the pharma 
value chain, leading to results, which reinforce the previous findings. In the case 
of Ireland, Brennan – Rakhmatllin (2015) analysed this industry based on the 
trade in value added (TiVa)2 database. They emphasize that in the pharma indus-
try there are producer driven value chains, similarly to other high-tech industries. 
In these value chains, the lead company controls the creation and design of the 
product and coordinates production shared by many countries (Backer – Mirodout 
2013). In the Irish economy, the pharma industry plays an important role. Based 
on the data they found that among the OECD countries, Ireland is among the 
first five countries in terms of its participation in chemical GVCs. According to 
the data, between 1995 and 2009, there has been a significant increase in local 
value added in Ireland in the export of the industry. While this is mainly due to 
the upgrading of production companies up till 2005, in 2009, the data indicate 
a quick growth of local suppliers (intermediaries). The backward and forward 
participation indexes also support that direction of change. At the same time, the 
share of services is high (one third) in local value added, the majority of which 
is fee for intellectual property (royalty). (This latter may indicate the inflating 
impact of the favourable Irish regulations on the data (Antalóczy – Sass 2014).) 
In terms of the distance from final demand, the Irish indicator is relatively high in 
international comparison, thus Ireland has specialised in the production of inputs 
and not in assembling, which is more beneficial in the case of the producer-driven 
value chains in terms of local impact and value added. Another positive indica-
tor from the point of view of the Irish economy is that the number of production 
2 https://www.oecd.org/sti/ind/measuring-trade-in-value-added.htm
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phases has grown between 1995 and 2009. However, because of methodological 
problems (TiVA presents aggregated data for the Chemical industry), we have to 
be cautious with these results.
There is another country level study on the GVC-related characteristics of 
the pharma industry: for France. Cezar (2016-17) used the WIOD (World Input-
Output Database)3 for his analysis. According to his results, the integration of 
the French pharma industry into global value chains has been realised quickly 
between 2000 and 2014. This is indicated among others by the quick growth of 
the import content of exports (from less than 15% to above 20%), which is in line 
with what we present in the case of Sanofi-Chinoin and partly to Egis-Servier. 
This indicates mainly the increase in foreign high-tech and mid-tech services. 
Nevertheless, this integration process seems to come to a halt after the crisis. 
The integration of the exporting companies is much stronger than that of those 
firms which only produce for the domestic market. The multinational companies, 
present on the French market are also better integrated than their French counter-
parts. In the local (operating only in the French economy) value chains, the contri-
bution of services has declined during the analysed period, the reason for which, 
according to the author, is the internationalisation of R&D activities. Overall, the 
integration in GVCs in the case of the French pharma industry brought with it the 
increase of the share of foreign value-added in both production and export, at the 
expense of local value added – which again underlines the description of what 
happened in the two French-related pharma privatisations in Hungary.
In a most recent study, Folfás – Udvari (2019) analysed the Hungarian and 
Polish chemical industries in terms of their participation in GVCs. They showed 
that, though with a declining tendency over time, pharmaceuticals have large do-
mestic value added compared to other branches of the chemical industry. Overall, 
the literature is not abundant in the analysis of the pharma value chain, which 
we attribute mainly to data problems becoming more serious in the era of the 
globalisation and the internationalisation of value chains. New data sources, such 
as TiVA or WIOD “provoked” new research in this area, the results of which 
give support to our previous analysis of the fate of the leading Hungarian pharma 
companies. Further, we could not find analyses of the CEE pharma industry from 
the GVC’s point of view. Furthermore, the analyses so far have not taken into 
account the original-generic distinction, in spite of the fact that it may result in 
completely different outcomes concerning the value chain organisation and up-
grading. Our article addresses these gaps in the literature.
3  http://www.wiod.org/home
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3. METHODOLOGY
With the proliferation of GVCs, in which more than one country participates in 
the production of a good, it is more and more difficult to map developments in the 
value chains of an industry. In the production, more locations from many coun-
tries take part, there is a substantial flow of goods and services between them, 
in many cases there are exports and imports of intermediary products and their 
further processing. Understandably, the export of a country contains not only the 
value added produced by local producers, but also the value added, arriving to 
the country with imported inputs, which are later built in the exported product 
(or final product consumed locally) (UNCTAD 2013; World Bank 2017). Thus, 
on the basis of the traditional, country and finished product level production and 
foreign trade statistics we cannot really detect how a country participates in inter-
national production, it is specialised in the production of which products, which 
industries and activities.4 
Considering the above described data problems, in our analysis, we rely on a 
combined methodological approach. First, we make an industry level analysis 
using input-output tables. The main advantage of using the national input-output 
tables is their comprehensive handling of the production and consumption proc-
esses including foreign links in terms of imports and exports. The input-output 
system offers the technical relations of the different industries or products both in 
supply and use, hence the national value chains can be traced. The system links 
production and trade statistics, which used to be calculated by different methods. 
One of the main benefits of the tables is the possibility to calculate the inverse 
matrices (and thus the Leontief matrix), which allows the researchers to detect the 
indirect effects. One of the main drawbacks is the time-consuming nature of data 
collection and harmonisation. This is why though there are yearly created supply 
and use tables, systemic input-output tables are more rarely published – in most 
cases every 5 years – with a number of years lag (Forgon 2008; Miller – Blair 
2009; Meng et al. 2012).
International organisations launched projects to extend the input-output sys-
tems to the international level, link and harmonise the national input-output ta-
bles. The OECD, World Bank and Eurostat databanks are the most often used. 
The OECD offers national tables as well as different indicators including the 
4  For handling this problem, there are two new databases available, such as WIOD (world input-
output database), and the TiVA (trade in value added) database, compiled by OECD-WTO. We 
opted for a combined methodological approach, because data in these datasets are not disag-
gregated to the required level for the pharmaceutical industry and do not contain indicators 
important for our analysis.
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inverse matrices and many linked indicators. However, the data base differenti-
ates only 36 sectors, combining the ISIC 20 and 21 categories, the chemicals 
and the pharmaceutical products. Eurostat provides national tables and input-out-
put coefficients only but differentiates 64 products by CPA classification, hence 
offers information directly on pharma industry, basic pharmaceutical products 
and pharmaceutical preparations (C21). The EU initiated the compilation of the 
World Input-output Database (WIOD), which lacks the calculation of indicators 
but offers internationally linked input-output tables on 43 countries and 56 sec-
tors where pharmaceutical products are also differentiated.
This research is based on the Eurostat input-output tables for Hungary, on the 
UNCTAD trade statistics and on the WIOD. Though this way the most reliable 
sheets provided data for 2010 only and we had to neglect several pre-calculated 
indicators; but the figures in use offer information directly for pharmaceutical 
products by the same classification.
Our second data source is quantitative: we conducted questionnaire-based, 
semi-structured interviews with leading managers of Hungarian pharma com-
panies in order to explain and understand the mixed results of our quantitative 
analysis. Our main aim was to map the value networks of the individual pharma 
companies. We conducted the anonymous interviews with 10 company managers. 
Among these, there are Hungarian-owned, controlled and foreign-owned compa-
nies. Our questionnaire tried to assess their links to local firms and other actors in 
three areas: R&D, production and other activities (HR-services, marketing, etc.) 
These two different methodological approaches supplement each other well 
and help us to overcome the data problems. We have a general picture about 
the Hungarian pharma industry based on the data, and then we can show the 
differences between the different groups of companies (mainly generic-original 
producer, large-medium and foreign-domestic-owned firms) with the help of the 
information gained from the company interviews. 
Finally, embedding the qualitative and quantitative information into the over-
all and historic prospective of the Hungarian pharma industry we can conclude 
some specialities of the pharmaceutical value chains in Hungary. 
4. RESULTS OF THE DATA ANALYSIS
Rather than discussing all details that can be learned from the input-output analy-
sis, our  paper focuses on the information that follows the research questions 
listed. 
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4.1. The domestic position and the domestic backward and forward linkages 
of the pharma industry
In terms of its overall weight, the national input-output analysis (20105) indicates 
that even if the pharmaceutical industry does not have a determining position, 
its relative contribution is significant (Figure 1). The total ratio, 1.85%, actually 
means a position in the first third of the 65 industries. The numbers reflect an in-
dustry, which has relatively high importance in international relations and in pub-
lic consumption of Hungary and create relatively high changes in inventories.
The total value added seems to be low both in absolute terms and, in compari-
son, to the ratio of the total production. However, it should be taken into account 
that the value-added figures of all industries are quite scattered – the highest 
value is 9%. Pharmaceutical production takes position in the second quarter of 
the industries.
5  Let us emphasise again that the available and comparative sources of the national and inter-
national systemic data for the pharmaceutical industry offered input-output tables for 2010 
the latest. However, the value networks prove to keep being stable over the long term and the 
technological changes have not yet repositioned the industries. Hence the pharma industry 
specialities can be revealed by the 2010 data, combined with up-to-date interviews.
6  There is no place to analyse and present the whole input-output table and the different indus-
tries. The table contains only the numbers of the pharmaceutical industry with reference in the 
text to its relative meaning among the other branches.
Figure 1a. Ratio of the pharmaceutical supply and use from the total (%)
Source: Own edition based on Eurostat input-output database.6
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The inner structure of the pharmaceutical industry (Figure 2) reveals that the 
pharma industry produces a relatively outstanding share of total value added, 
one fourth of its production. This share is the highest among all manufacturing 
industries. One can also learn that both the pharma production and consumption 
chains are internationally networked to a great extent. Moreover, the industry 
offers a relatively high profit rate. Though the operating surplus content of the 
value added exceeds wages, its rate is high at the national level. 
Figure 2. The structure of the pharmaceutical production and use (%)
Source: Own calculation based on Eurostat input-output database.
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Regarding the length and the structure of the domestic value chains, the tech-
nology matrix indicates that the pharmaceutical industry is rather concentrated 
on relatively few local chains compared to other industries. As for the backward 
linkages, 20.6% of the intermediate production is a supply from different inter-
mediaries of the pharmaceutical industry itself, two thirds derive from only 9 dif-
ferent branches, among which three are linked to chemical industries, one is elec-
tricity. The remaining industries are different operation services, except for the 
R&D value chain (3.4%), which is both in absolute and relative numbers among 
the highest values. (Figure 3)
Forward linkages are even more concentrated; just four product groups con-
sume two thirds of the total pharma production. The leading ones are human 
health services and the pharmaceutical industry itself. 
Figure 3. Domestic backward linkages of the pharmaceutical production 
(% of the total intermediaries)
Source: Own calculation based on Eurostat input-output database.
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All in all, the domestic input-output figures introduce the Hungarian pharma 
industry as one which nationally has an important but not outstanding position. 
Its domestic value chains are relatively short and concentrated with a focused 
role of the pharma industry itself both in the backward and forward value chains. 
However, the pharma industry produces the highest value added among the man-
ufacturing industries, and reflects a relatively high research and development ra-
tio. Finally, the total concentrated network is deeply involved in the international 
value chains both in terms of export and import. We should follow and discuss 
more on the foreign relations of the pharmaceutical industry.  
Figure 4. Domestic forward linkages of the pharmaceutical production 
(% of the total intermediaries)
Source: Own calculation based on Eurostat input-output database.
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4.2. Trade positions and the international backward and forward value chain links
To detect the trade positions Annex Table 17 lists some important indicators of the 
pharma trade in a rank of the main industries. Relating to the general economy, 
the pharmaceutical industry has a moderate participation in overall exports and 
imports, though it appears among the top ten trading industries in Hungary. 
The different chemicals and the related industries all show trade deficits, with 
relatively low values related to the pharmaceutical products. The time series of 
net trade in Figure 5 reflects that the permanent deficit position changed in 2010, 
and until 2016 the industry performance was either balanced or reflected a slight 
surplus. In 2017, the extent of the value of the backward linkages again overcame 
that of the upstreaming relations.
Adding the foreign trade coverage ratio, the relatively small deficit with a 
coverage value lower than but close to 1, projects a relatively high level of trade 
flows. 
The inter- and intra-industry trade flows offer more information about the val-
ue chains of an industry. In the Hungarian economy while the leading industries 
have high Gruber-Lloyd index: close to 1, meaning a high level of intra-industry 
trade, the 0.46 value for pharmaceutical products rather reflects inter-industry 
7  Some large tables and graphs are put to Annex so that they do not break the continuation of the 
discussion.
Figure 5. Gross and net trade flows of the medical and pharmaceutical products in Hungary
(thousand dollars)
Source: Own edition based on UNCTAD figures.
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trade dominance. It seems that while some determining industries produce in 
long value chains, such as computers, motor vehicles and even rubber and plas-
tics in chemical industries, the pharmaceutical production chain rather shrank.
The Balassa Revealed Comparative Advantage (RCA) indicates that Hungary 
has a very slight comparative advantage in medical products. Figure 6 shows the 
evolution of RCA over time. After the transition process started, there was a fall 
in pharma exports, due to privatisation and the collapse of the Russian market. 
The specialisation in pharmaceutical products has increased since 1995, mainly in 
the case of medicaments. However, even if RCA is taken usually as an indicator 
of comparative advantage, the increasing relative ratio does not necessarily mean 
an increasing value added content of export; hence the domestic value added may 
even fall due to the increasing import of intermediaries and the engagement of 
production factors in low value added products and chains.
Linking the supply and demand sides of the national input-output accounts 
enables to detect the value added and import content of export (Table 2). The 
technological coefficients and the Leontief inverse matrix reveal that regarding 
the direct domestic relations of the industries, the pharmaceutical value added 
of export is quite low, only 8%, while the national average is 19%. However, 
considering the indirect relations too, the domestic value added content of phar-
maceutical exports reaches 35%, the highest among the leading manufacturing 
industries. This means that even if the pharma industry has a relatively high value 
added content, the majority of the value added export comes from the backward 
chain industries. 
The international value chains of pharmaceutical production also depend on 
how the import content of supply contributes to export. The direct and indirect 
Figure 6. Change in RCA of pharmaceutical products
Source: Own figure based on UNCTAD data base.
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import ratio of export is 64%, which means that two thirds of the export value of 
the pharmaceutical products comes from direct imports as well as from imports 
used in the production of domestic intermediaries.
The import matrix (Table 2) reveals the internationally linked backward and 
forward industries of the pharma value chain. Similar to the national value chains, 
the industry is linked internationally to pharmaceutical and to other chemical 
products. This represents almost half of the import. The rest consists mainly of 
other chemical products and different services; however, it is worth noting the 
relatively high proportion of the foreign R&D contribution. As far as pharmaceu-
tical consumption is concerned, we have found that about one third of the total 
pharmaceutical import is used in the production of other industries; of which Ta-
ble 2 indicates that human health services as well as the pharmaceutical industry 
itself consumes the most. 
The international input-output databases and the calculated inverse tables of-
fer even more new insights. They make it possible to involve the different coun-
tries by industries to detect the downward and upward linkages (Annex Tables 
2 and 3)8. The overall learning is that both the backward and forward linkages are 
8  It is important to note that the WIOD table is based on industry x industry, while the Eurostat 
data were product x product based. The Hungarian figures and ratios hence differ from the 
earlier tables.
Table 2. The main backward and forward linkages of the pharmaceutical production by industry 
in terms of import (% of total)
Imports to pharmaceutical supply Sectors importing pharmaceutical prod-
ucts
Basic pharmaceutical products and phar-
maceutical preparations
27.1 Human health services 34.2
Chemicals and chemical products 21.2 Basic pharmaceutical products 
and pharmaceutical prepara-
tions
27.0
Wholesale trade services, except of motor 
vehicles and motorcycles
 6.1 Motor vehicles. trailers and semi-
trailers
 5.7
Legal and accounting services; services 
of head offices; management consulting 
services
 5.9 Chemicals and chemical products  4.1
Security and investigation services; services 
to buildings and landscape; office admin-
istrative, office support and other business 
support services
 5.4
Scientific research and development services  4.6
Source: Own compilation based on the import matrix of Eurostat input-output tables.
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scattered among a number of countries but they are more concentrated in terms 
of values. In the backward links, the European, mainly Hungarian and German 
chemical and service industries dominate. The forward chains reach out mostly 
to the USA, Russia and China, where pharma products for final consumption 
dominate rather than intermediaries. The details are as follows: The international 
production (backward) chain of the pharmaceutical products of Hungary consists 
of 300 different units in 36 different countries. Most of them are from Europe, 
outside Europe the USA leads (6 industries), followed by Korea (5), Japan (2), 
Taiwan (1) and Russia (1). The dominant countries are European: Hungary (49) 
and Germany (27), followed by Austria (16), Poland (15) and Italy (15). Among 
the industries, 19 are manufacturing, mostly chemical (32), pharmaceutical (24) 
and rubber (17). However, the majority are services, mainly wholesale trade, le-
gal and accounting services. 
Though the number of chain links is high, by value it is more focused: one 
third of the total output comes from 9 sources only, mainly from Hungarian and 
German industries. It is interesting to see that in Hungary mostly the service sec-
tor contributes and then the chemical industry. The other countries list their phar-
maceutical or chemical industries in the following country order regarding inter-
mediary values: Germany, Switzerland, Austria, France, Czech Republic, Great 
Britain, Italy, Belgium, Russia and the Netherlands (75% of the total value).
As far as the forward chain is concerned (Annex Table 3), 326 different units 
are present in 40 countries. On the export side, more non-European countries 
appear, USA (14 units with 12 industries among them), Russia (12) China (5) 
Canada (3), Brazil (3), Indonesia (3), Australia (2) and Japan (2). There are more 
dominant countries in terms of the number of chain links: Hungary (42 industry+4 
final use), Italy (19+4) and Germany (17+4), then Poland (12+3), France (11+3), 
Czechia (10+3), Romania (10+3), The Netherlands (10+3), Slovakia (7+4), Aus-
tria (7+3) and Denmark (6+4). However, the forward links are also concentrated: 
5 links give the first third of the total value and 11 represent 50%. It is remark-
able that 75% of the total value mainly consists of final consumption; only Italy, 
Czechia, Switzerland and Great Britain import Hungarian pharmaceutical prod-
ucts for human health or pharmaceutical manufacturing.
All in all, the international input-output analysis revealed more pharma indus-
try specialities. The industry is foreign market oriented to a great extent both in 
terms of export and import. However, the value-added content of export is rela-
tively low and can mainly be derived from the foreign backward industries. The 
R&D content of the industry’s value added is relatively high, though its majority 
is also concentrated in the backward value chains outside the country. The in-
ternational backward and forward linkages are quite concentrated both domesti-
cally and internationally, though not to the same extent in terms of countries and 
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industries. On the backward side the European countries, mainly Germany and 
Austria, dominate, while regarding the forward linkages, the importance of the 
non-European partners, such as US, Russia, China is relatively higher.
These results indicate a characteristic industry profile. However, the historic 
overview highlighted that the main traditional pharmaceutical companies were 
launched with different specialisation, followed different production patterns and 
they were privatised in different ways. Hence our research must not neglect the 
individual features, or more precisely those characteristics that differentiate the 
main companies from each other and contribute to a detailed value chain analysis. 
We need to turn to the primary sources of our analysis: to the interviews in order 
to detect further industry specialties.
5. RESEARCH RESULTS BASED ON COMPANY INTERVIEWS
In order to partly explain and partly supplement the results of the quantitative 
analysis, we took anonymous interviews with ten pharma managers, where we 
tried to enquire about their contacts with local and foreign economic and non-
economic agents. Our questionnaire tried to assess these links with domestic 
firms and other actors in three areas: R&D, production and other activities (HR-
services, marketing, etc.). In our sample, we had all the leading pharma firms in 
Hungary (four companies, all majority foreign-owned, one domestically control-
led), four medium-sized Hungarian companies, and two small-sized biopharma 
firms. Furthermore, we have conducted an interview with the representatives of 
MAGYOSZ, the association of Hungarian pharma firms.
Table 3. Basic characteristics of the interviewed companies (2017)
Majority 
ownership
Size Original – Generic R&D expenditure/
sales, %
Export/
sales, %
A foreign large original/generic 9.1 90
B foreign large generic 8.5 77
C foreign large generic/original 22.5 32
D foreign large generic 1.0 84
E domestic medium generic 15.0 13
F domestic medium generic 2.0 87
G domestic medium generic 3.0 19
H domestic medium original (biotech) 40.0 99
I domestic small original (biotech) 12.0 9
J domestic small original (biotech) 14.0 9
Source: Authors’ compilation (data from the balance sheets and supplements of the companies).
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Our interviewed managers reinforced the observations about the differences 
between the original and generic value chains. The original value chain is more 
complex, longer and in principle involves more links with other companies and 
industries-activities.  The difference between the two value chains can be found 
mainly in the first phase: the R&D activities of the original companies and activi-
ties involve more stages, are more complex and embrace a longer time period. 
They require extensive relationships with research institutes, universities, other 
firms and clinics. The generic value chain is shorter, less complex and has a 
lower number of links outside of the company. As we already noted, the Hungar-
ian pharma producers are mainly generic ones. The manager of firm “A” under-
lined that in companies, where both generic and original activities are present, the 
value chains of the two are treated separately, they are separated from each other 
from the organisational point of view as well. In the case of company “B”, the 
foreign owner of which is a company with both generic and original profile, this 
means that the parent firm has the whole original value chain, while the generic 
one “belongs” to the Hungarian affiliate, involving all activities from generic 
R&D, through production, sales to marketing. Decisions of strategic importance 
are taken by the foreign owner, thus the Hungarian pharma producers’ domestic 
value chains and the related linkages are determined by their ownership structure 
and the strategy of their owners. As the manager of company “A” noted: “The de-
velopment and marketing of a molecule consists of thousands of different steps. 
Each step involves a decision: whether to keep it within the company or outsource 
it?” In the case of company “C” – in a similar situation, in the ownership of a 
foreign multinational company with both generic and original production – the 
owner has reorganised the value chain many times in the last 30 years. At present, 
the Hungarian affiliate retained only a part of the generic value chain, production. 
The first part of the value chain, R&D activities have almost completely been 
transferred away from Hungary, while the parent company established the CEE 
logistics centre here, and from the last parts of the value chain, only the Hungary-
focused marketing remained here – even this latter in a special organisational 
construction. In the case of company “D”, the parent company has just a generic 
profile. For its Hungarian affiliate, it “cut” the first and last parts of the value 
chain, and basically just the production activities remained in Hungary. At the 
same time, this part of the value chain has been developed to an extent where the 
Hungarian affiliate is the second most important production site in the network 
of the multinational firm, and thus, it is of strategic importance. Company “A” 
has both generic and original value chains, both of them in a very complex form, 
because the Hungarian management decides about the value chain activities due 
to the dispersed ownership structure of the company. Thus, in the case of the 
four leading firms, the relationship with and links to other firms and industries is 
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determined by the length, complexity and nature of the value chain in Hungary 
and the strategy of the management. In the case of the other interviewed smaller 
firms, generic activities dominate; they concentrate on a few products compared 
to the big firms, with shorter and less complex value chains.
In principle, the highest number of linkages with firms is available in the R&D 
phase, especially in the case of the original companies. This was reinforced by 
the interviews: we found the strongest and most frequent cooperation links in 
the area of R&D, in many cases with local companies, or other local institutes 
(universities or public and private research institutes). However, by far the high-
est frequency was found in the case of company “A”, which has both generic and 
original arms. 
We found many cases when outsourcing of certain R&D activities was real-
ised. Similarly, the large pharma firms, which have intensive R&D, indicated that 
they outsource basic research activities to universities, research institutes or small 
biotechnology firms. Medium-sized firms had a similarly intensive outsourcing of 
R&D, one firm in our sample even indicated that the value of within and outside 
company R&D is similar. Smaller firms have similarly close cooperation links 
in R&D, however, in their case they carry out such activities for other firms as 
well. Company “E” for example, a medium-sized Hungarian pharma firm, with 
technology-related R&D, outsourced measuring activities to a Hungarian univer-
sity and cooperates with various Hungarian universities. To a limited extent, they 
carry out R&D activities for Hungarian and foreign pharma firms. A small firm 
in our sample, company “I” is actively seeking for outsourced activities from 
large pharma firms, and the revenues from these activities are used for financing 
own R&D of the small firm. The companies in our sample regarded clinical trials 
as part of R&D activities. In this area they had intense links with foreign-owned 
companies operating in Hungary, with Hungarian companies and in certain cases 
with those hospitals (or workers of hospitals) which provide such services. For 
example, one firm in our sample, company “G” outsourced clinical trials related 
IT activities to a Hungarian company. Basically, all companies evaluated these 
R&D links as long-term, though in certain areas and with certain economic actors 
they have short to medium term cooperation. However, long-term cooperation 
dominates. Almost all cooperation partners receive various help: mainly train-
ings, quality insurance, donation of equipment, providing information or advice. 
Only one company was an exception in our sample, according to which this help 
was negligible from its partners. All companies are members of various industrial 
or other chambers or associations in Hungary, which helps them in finding part-
ners for outsourcing and cooperation.
As for the intensity and importance of these relationships: we asked whether 
the loss of these would impact upon the company’s operations strongly. All com-
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panies in our sample indicated a strong impact, however, the strength of this 
correlated negatively with company size: the larger the company, the smaller the 
impact.
The other area of the analysis of local links was production – whereby we could 
not trace the same intensity and frequency of local cooperation as in the case of 
R&D – reinforcing our results for the importance of the R&D part of the value 
chain in terms of local impact. The companies in the sample rely to a very lim-
ited extent on local suppliers, which is partly due to the above described ‘short-
ness’ of the value chain, as the companies keep the majority of the value chain 
within them. Among the suppliers we can find producers of packaging material, 
producers of specialised machinery, chemical firms, and suppliers of raw materi-
als. For example, company “H” in our sample buys packaging foil, boxes and 
alcohol from Hungary, and the molecules from abroad. None of the interviewees 
quantified the value of various inputs, but all of them indicated that they are of 
minor importance. In all cases, the share of local suppliers is dominant, above 
60%. However, in many cases the substances originate from abroad. One foreign-
owned firm, company “B” mentioned that many traditional suppliers of the par-
ent firm established a subsidiary in Hungary to provide local supply, so we can 
assume that in the case of the other firms, such local supplies (by foreign-owned 
companies) are also important. The companies hardly bought high-tech products 
from these suppliers, with the exception of one interviewed firm. According to 
the opinion of managers, they all ranked the importance of production-related 
links and partners lower compared to R&D. This low role of local suppliers in 
production can be explained partly by the high requirements concerning the sup-
pliers. Quality requirements are high, and they require a complex quality insur-
ance system. Furthermore, flexible delivery time and financing constructions are 
also needed. In the 90s, many traditional Hungarian suppliers could not bear the 
intense competition, and thus, there has been an increase in imported supplies. Ac-
cording to our interviewees, in the nineties, the group of suppliers was not stable; 
however, since then there is a stabilisation in this respect. Interestingly enough, 
the composition of suppliers, according to the ownership (foreign and domestic) 
is determined not by the ownership structure of the firm in question, rather by its 
product structure (Antalóczy 1997). As our interviewees noted, requirements and 
regulations of the export markets and whether the finished product dominates, 
determines this composition. For export markets with high requirements, good 
quality inputs are used, which are in many cases imported from abroad. 
Similarly, less intense and less close is the partnership with suppliers in other 
areas. For example, in the area of services, certain services are acquired from lo-
cal suppliers in the case of all companies both regularly (infrastructure and office 
maintenance) and occasionally (HR and headhunting). We could put clinical tri-
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als in this category as well. These are present in all company cases, with varying 
intensity. The smaller sized firms choose mainly local(ly available) suppliers, 
while the large ones choose the leading companies in the area. One must also 
mention partnership with trading firms. However, overall, these partnerships are 
of lesser importance for all firms.
6. CONCLUSIONS
Our input-output analysis supported the common knowledge that the pharma-
ceutical industry has a significant position in the Hungarian economy. It has an 
important share in output, in export and even more in import. Specialisation in the 
pharma products has increased since 1995 as well as a slight comparative advan-
tage can be detected. The industry’s gross trade flow is considerable with strong 
positions in the imports though less determining in the exports. 
The value added content of the production is relatively high with a propor-
tionally greater share of operating surplus in contrast to wages. As far as the 
industry specific production structure is concerned, the value chain of the pharma 
industry is different from those of other industries. Its technological relations do 
not demand and its highly regulated nature does not allow a wide range of back-
ward or forward linkages. The domestic value chain structure in Hungary is quite 
concentrated with a few local chains only. The input-output data reflect that the 
inter-industry (chemical) backward relations of the pharma industry are relatively 
high. The forward linkages are even more focused: most of the output appears in 
the final use, mainly among health services and partly in export. 
The international links of the Hungarian pharma value chains are also con-
centrated both in terms of inter-industry relations and of the partner countries. 
The majority of the backward links run via Central Europe, mainly in Hungary 
and Germany. The international forward value chains spread among more coun-
tries; however, still remain concentrated, and the destination is mainly the non-
 European final consumption.
The structure of the value chain is also considerable. The pharmaceutical chain 
is not only short but also uneven in terms of the value added. Even if the phar-
maceutical export has relatively high value content, two thirds of it derives from 
the direct and indirect import. The figures support that the domestic contribution 
to the value added is quite low. The type of the value chain further distinguishes 
the value added content and the possible participation in the production. The 
interviews highlighted that the value chains of the original and the generic pro-
duction processes essentially vary. The original value chains are longer and more 
complex with a high R&D content in the beginning stage. In Hungary, most of the 
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pharmaceutical production is generic with a relatively shorter and simpler value 
chain structure; or in case both the organic and the generic are present, they are 
separated and mainly the modest value-added production phases of the organic 
process remain. 
The historic embedding contributed much to the understanding of the pharma-
ceutical specialties. The original companies launched different value chain paths 
by their special original-generic structure. In the CMEA period, the increase of 
the value-added potential was highly motivated since the pharmaceutical indus-
try had a special role in the East-West economic strategy. This relative corporate 
and national wealth turned a new period by the different modes of privatisation. 
Further division of the relatively short value chain has made the industry even 
more specific. At the same time, the owners made a selection of the activities 
in the value chains based on their efficiency and potential, and moved the most 
promising activities (in certain cases whole chains) outside the country.  Thus, 
the mode of privatisation was of determining importance from the point of view 
of further development of the Hungarian pharma industry: where same-industry 
foreign owners appeared, the above changes in the value chain resulted in nega-
tive or ambiguous impact on the Hungarian value chain. Further, the Hungar-
ian controlling owners (with foreign majority ownership) could keep full value 
chains – though mainly generic, only some original – within the country.
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Annex Table 3. The forward international value chain of the Hungarian pharmaceutical products 
in the rank of the total use, %
Product
code
Intermediate consumption or final use Country 
code
Total Cumulated 
Final consumption expenditure by households ROW 14.62 14.62
Final consumption expenditure by households ROU 7.47 22.09
Final consumption expenditure by households POL 4.62 26.71
Gross fixed capital formation HUN 4.28 30.99
Final consumption expenditure by government FRA 3.66 34.65
Final consumption expenditure by government ROU 2.95 37.60
Final consumption expenditure by households GBR 2.94 40.54
Final consumption expenditure by households BGR 2.92 43.46
Final consumption expenditure by government DEU 2.44 45.90
Q Human health and social work activities ITA 1.97 47.88
C21 Manufacture of basic pharmaceutical products 
and pharmaceutical preparations
ITA 1.94 49.82
Source: Own calculations based on WIOD.
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Annex Figure 1. Specific value chain of original pharma firms
* INDA – investigational new drug application 
** NDA – new drug application
*** CSR / PR – corporate social responsibility / public relations
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Annex Figure 2. Specific value chain of generic pharma firms
* ANDA – abbreviated new drug application 
*** CSR/PR – corporate social responsibility, public relations
Source: Dankó (2011).
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